Benign Prostatic Hyperplasia Medical Services in China

Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland commonly affecting men over 50. As the prostate grows, it compresses the urethra, leading to lower urinary tract symptoms—including urinary frequency, nocturia, weak stream, hesitancy, incomplete bladder emptying, and, in advanced cases, acute urinary retention or bladder stone formation. While BPH is not associated with increased prostate cancer risk, untreated progression may cause irreversible bladder dysfunction, upper urinary tract dilation, or renal impairment. Diagnosis relies on clinical assessment (IPSS questionnaire), digital rectal examination, uroflowmetry, post-void residual volume measurement, and transrectal ultrasound; PSA testing helps exclude concurrent malignancy. Management ranges from watchful waiting and alpha-blockers/5-alpha-reductase inhibitors to minimally invasive procedures (e.g., transurethral resection of the prostate—TURP, holmium laser enucleation—HoLEP, or bipolar vaporization) and, rarely, open prostatectomy.

China offers distinct advantages for BPH treatment: its urology centers—especially tier-1 hospitals in Beijing, Shanghai, and Guangzhou—employ internationally trained specialists with extensive experience in high-volume, complex cases. Advanced technologies such as thulium and holmium lasers, image-guided ablation systems, and robotic-assisted platforms are widely available and routinely used. Clinical outcomes align with global benchmarks: HoLEP demonstrates >95% symptom improvement at 5-year follow-up, with low retreatment rates. Crucially, costs for surgical intervention in China are typically 40–60% lower than in the US or Western Europe—without compromising safety or efficacy. As a dedicated medical tourism agency, we facilitate seamless care for international patients: verifying hospital accreditation, coordinating consultations and surgery scheduling, providing transparent all-inclusive pricing (covering diagnostics, procedure, accommodation, and interpreter services), and offering end-to-end support—from visa assistance to postoperative follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Benign Prostatic Hyperplasia (BPH)

Non-Surgical / Conservative Management

*Indicated for mild-to-moderate symptoms (IPSS ≤19), no urinary retention, Qmax ≥10 mL/s, prostate volume <80 mL, no significant comorbidities.*

• •Alpha-blockers (e.g., tamsulosin): ¥45–¥120/month ($6–$17)
• •5-alpha reductase inhibitors (e.g., finasteride): ¥60–¥180/month ($8–$25)
• •Combination therapy: ¥100–¥300/month ($14–$42)
• •Baseline diagnostics: PSA test (¥120), transrectal ultrasound (TRUS) (¥380), uroflowmetry + post-void residual (PVR) (¥220) → Total: ¥720 ($100)
• •Annual monitoring: PSA + TRUS + symptom assessment → ¥650 ($91)

Surgical / Interventional Options

*Eligible for moderate-to-severe BPH (IPSS ≥20, Qmax <10 mL/s, recurrent UTI, bladder stones, renal impairment, or failed medical therapy).*

• •Transurethral Resection of the Prostate (TURP)

- Procedure + 3-day hospital stay (Grade 3A public hospital): ¥18,500–¥24,000 ($2,590–$3,360)

• •Holmium Laser Enucleation of the Prostate (HoLEP)

- Procedure + 2-day stay: ¥26,000–¥32,000 ($3,640–$4,480)

• •Transurethral Bipolar Enucleation (ThuLEP)

- Procedure + 2-day stay: ¥23,000–¥28,500 ($3,220–$3,990)

Special/Complex Condition Management

• •BPH with large prostate (>100 g) or bladder calculi: HoLEP preferred; add cystolitholapaxy (+¥3,500–¥5,200 / $490–$730).
• •BPH with chronic urinary retention requiring catheter dependence: Requires pre-op bladder training + urodynamics (¥1,800 / $252); TURP/HoLEP cost increases by ¥2,000–¥4,000 ($280–$560).
• •High-risk patients (severe CAD, anticoagulation): ThuLEP or laser vaporization (GreenLight PVP); PVP procedure cost: ¥21,000–¥27,500 ($2,940–$3,850).

Quick Selection Guide

• •Age <65, budget-constrained, IPSS 12–18: Start with alpha-blocker monotherapy ($6–$17/month) + annual monitoring ($91).
• •Age 65–80, moderate symptoms, prostate 40–75 g: TURP offers best long-term durability ($2,590–$3,360) and is covered by basic医保 (insurance).
• •Prostate >80 g or anticoagulated: HoLEP ($3,640–$4,480) — superior hemostasis, lower reoperation risk.
• •Severe comorbidities (COPD, heart failure): GreenLight PVP ($2,940–$3,850) — shorter catheter time, outpatient-capable in select centers.
• •Recurrent retention or renal impairment: Urgent HoLEP or ThuLEP; avoid delayed intervention—costs rise 20% if acute retention precedes surgery.